Business Context and Reporting Period
Company: Interlink Electronics, Inc. (LINK)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: Interlink is a provider of sensors and printed electronics for Human-Machine Interface (HMI) and Internet-of-Things (IoT) solutions. Key markets include medical, industrial, automotive, and wearables. The company operates manufacturing facilities in the U.S., China, and the U.K.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $2,959,000 | $2,671,000 | $9,037,000 | $8,693,000 |
| Gross Profit | $1,238,000 | $1,105,000 | $3,725,000 | $3,663,000 |
| Gross Margin | 41.8% | 41.4% | 41.2% | 42.1% |
| Net Loss | $(336,000) | $(523,000) | $(1,041,000) | $(1,571,000) |
| Net Loss to Common | $(436,000) | $(623,000) | $(1,341,000) | $(1,871,000) |
| Diluted EPS | $(0.03) | $(0.04) | $(0.09) | $(0.13) |
| Cash & Equivalents | $2,987,000 | $3,810,000 (Q3 24) | Balance Sheet: $2,987,000 (Sep 30, 2025) | |
| Working Capital | $4,880,000 | Calculated: Current Assets ($6.4M) - Current Liab ($1.5M) | ||
| Debt | $0 | No indebtedness reported; liabilities consist of leases and payables. |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 revenue increased 10.8% year-over-year (YoY) to $2.96M. Nine-month revenue increased 4.0% YoY to $9.04M.
- Profitability Improvement: Net loss narrowed significantly in Q3 2025 ($0.34M) compared to Q3 2024 ($0.52M). Operating loss improved from $(0.48M) to $(0.31M) in Q3.
- Expense Management: Engineering and R&D expenses decreased 27.2% in Q3 and 26.8% in the nine-month period, primarily due to lower employee and consultant compensation. SG&A expenses increased slightly in Q3 (9.3%) due to higher professional fees but remained flat for the nine-month period.
- Market Mix Shift: In Q3, medical revenue surged 88.9% while industrial revenue declined 27.9%. Over the nine months, industrial revenue grew 12.5% while medical revenue declined 7.7%.
- Cash Flow: Operating cash flow turned positive, providing $244,000 in the first nine months of 2025, compared to a use of $144,000 in the same period in 2024.
Guidance, Outlook, and Risks
- Capital Structure Change: On October 15, 2025, the company converted all 200,000 shares of Series A Convertible Preferred Stock into 900,000 shares of common stock. This eliminates the annual dividend obligation of $400,000 previously paid to preferred shareholders.
- Stock Dividend: A 50% common stock dividend was declared in September 2025 and paid in October 2025. All historical share and per-share data in the filing have been retroactively adjusted.
- Financing: The company has an At-The-Market (ATM) issuance agreement allowing for the sale of up to $6.0M of common stock. Through September 30, 2025, approximately $188,000 in gross proceeds were raised under this agreement.
- Liquidity: Management believes existing cash ($3.0M) and working capital ($4.9M) are sufficient for current operations. However, future funding may be required via equity or debt, which could result in dilution or restrictive covenants.
- Risks: Key risks include customer concentration (one customer accounted for 21% of Q3 revenue), supply chain disruptions, foreign currency fluctuations, and the ability to utilize net operating loss carryforwards (NOLs) due to valuation allowances.
Investor Verification Checklist
- Preferred Stock Conversion: Verify the impact of the October 2025 conversion of Series A Preferred Stock on future earnings per share and cash flow (elimination of $400k annual dividends).
- Customer Concentration: Monitor the stability of "Customer A," which represented 21% of Q3 revenue and 33% of accounts receivable.
- Medical Market Volatility: Assess the sustainability of the 88.9% Q3 revenue spike in the medical sector versus the 7.7% decline over the nine-month period.
- ATM Utilization: Track the remaining capacity ($5.8M) under the At-The-Market sales agreement and potential dilution from future issuances.
- Foreign Cash Repatriation: Note that $1.8M of the $3.0M cash balance is held by foreign subsidiaries; verify potential tax implications if these funds are repatriated for U.S. operations.